Cadila healthcare
Highlights from the management commentary
CDH expects NDA filing of Saroglitazar Mg for PBC indication in the US by CY23-end.
It submitted Phase 2b application of Saroglitazar Mg to the USFDA for NASH indication (Non-Alcoholic Steatohepatitis).
With respect to Desidustat, CDH has completed patient enrollment for Phase III trials in India for treatment of anemia in patients with Chronic Kidney Disease (CKD).
One of the 505b2 products has a PDUFA goal date of Sep’21.
The management expects to launch 30-35 products in the US in FY22.